Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis®

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This is a randomized, double-blind, comparative, parallel group study of the efficacy, safety pharmacokinetics, and immunogenicity of GNR-067 and Lucentis® in patients with neovascular (wet) age-related macular degeneration.
Epistemonikos ID: c7506942d5b92d758efc0ef9bc1062f498963437
First added on: May 08, 2024